Abivax SA Sponsored ADR (ABVX) AI Stock Analysis

• Market Cap: $5.53B
• Dividend Yield: N/A
• Average Volume (3M): 2.51M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.47
• Revenue Growth: N/A
• EPS Growth: 18.47%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.97
• Shares Outstanding: 75,573,510
• 10 Day Avg. Volume: 1,052,427
• 30 Day Avg. Volume: 2,509,398
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.07
• Enterprise Value/Revenue: 35.60
• Enterprise Value/Gross Profit: 35.60
• Enterprise Value/Ebitda: -4.47
• 1Y Price Target: $84.43
• Price Target Upside: 13.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 49 Neutral
• Price Target: $68.00 ▼(-8.64% Downside)

Abivax SA's overall stock score is primarily impacted by its poor financial performance, characterized by operational losses and high leverage. While technical analysis shows bullish momentum, the valuation remains unattractive due to negative earnings. Without additional positive catalysts or improvements in profitability, the stock faces significant risks.

Positive Factors

Clinical Data Performance

Obefazimod exceeded investor and company expectations on the FDA primary endpoint of clinical remission, achieving significant benefits across all primary and key secondary endpoints.

Market Potential

Obefazimod now has the most compelling late-stage clinical profile for a novel oral agent in ulcerative colitis with potential to address a clear unmet need in the massive ~$30bn market for IBD therapeutics.

Regulatory Pathway

Both doses of obefazimod met European Medicines Agency co-primary endpoints, strengthening confidence in the potential for regulatory approval.

Negative Factors

Dose Efficacy Comparison

The lower 25mg QD dose was not statistically significant on clinical remission in ABTECT-2, although other relevant endpoints were significant.

Abivax SA Sponsored ADR Business Overview & Revenue Model

Company Description

Abivax SA is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic treatments for inflammatory diseases and viral infections, including its lead product candidate ABX464, which is being investigated for the treatment of ulcerative colitis and other indications. The company operates primarily in the biotechnology sector, leveraging its proprietary technologies to discover and develop innovative therapies that address significant unmet medical needs.

How the Company Makes Money

Abivax generates revenue primarily through funding from investors and partnerships in the biopharmaceutical industry. The company does not currently have commercial revenue from product sales, as it is still in the clinical development phase. Its revenue model is primarily reliant on securing grants, collaborations, and potential licensing agreements with larger pharmaceutical companies. Successful clinical trial outcomes can lead to milestone payments and royalties from partnerships, which can significantly contribute to its financial resources as it progresses towards commercialization.

Abivax SA Sponsored ADR Financial Statement Overview

Summary

Abivax SA faces significant financial challenges with consistent operational losses and reliance on debt financing. While revenue is growing, profitability remains a concern with high operating losses and negative cash flows. These factors underscore the need for strategic improvements to enhance financial stability.

Income Statement

The company has shown significant revenue growth from the previous year, but still operates at a loss with negative net profit and EBIT margins. The gross profit margin remains stable, yet the high negative EBIT and net income suggest ongoing operational challenges.

Balance Sheet

The company's balance sheet indicates high leverage with a substantial debt-to-equity ratio, but it has managed to maintain a reasonable equity ratio. The return on equity remains negative due to continued losses, suggesting difficulty in generating shareholder value.

Cash Flow

Cash flow from operations is negative, reflecting operational struggles, although there is positive free cash flow growth due to reduced capital expenditures. The company relies heavily on financing activities to manage its cash needs, indicating potential liquidity risks.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.79M	4.62M	4.58M	37.00K	63.00K
Gross Profit	10.79M	4.57M	4.47M	-119.00K	-33.77M
EBITDA	-171.88M	-133.21M	-53.31M	-38.59M	-38.00M
Net Income	-176.24M	-147.74M	-60.74M	-42.45M	-37.55M
Balance Sheet
Total Assets	205.23M	327.06M	75.54M	109.23M	71.30M
Cash, Cash Equivalents and Short-Term Investments	144.22M	260.99M	26.95M	60.70M	29.30M
Total Debt	97.36M	55.46M	49.23M	51.65M	33.99M
Total Liabilities	164.64M	131.05M	68.36M	83.30M	53.40M
Stockholders Equity	40.58M	196.01M	7.19M	25.93M	17.90M
Cash Flow
Free Cash Flow	-154.72M	-100.28M	-54.26M	-47.30M	-30.72M
Operating Cash Flow	-154.07M	-100.01M	-53.94M	-45.66M	-29.82M
Investing Cash Flow	15.76M	-10.49M	-12.03M	-1.46M	-575.00K
Financing Cash Flow	28.21M	340.57M	32.21M	78.51M	49.93M

Abivax SA Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 74.43
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVX, the sentiment is Positive. The current price of 74.43 is above the 20-day moving average (MA) of 70.83, above the 50-day MA of 36.68, and above the 200-day MA of 14.55, indicating a bullish trend. The MACD of 10.12 indicates Positive momentum. The RSI at 82.10 is Negative, neither overbought nor oversold. The STOCH value of 84.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABVX.

Abivax SA Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	€5.97B	17.37	-3.61%	2.14%	0.53%	-36.19%
ABVX	49 Neutral	$5.53B	―	-147.48%	―	―	18.47%
CELC	44 Neutral	$2.09B	―	-134.54%	―	―	-25.61%
ALMS	43 Neutral	$478.70M	―	-66.35%	―	―	-25.20%
ORIC	43 Neutral	$941.12M	―	-43.82%	―	―	-7.33%
AUTL	41 Neutral	$465.75M	―	-52.18%	―	187.52%	26.32%
ERAS	34 Underperform	$431.18M	―	-31.16%	―	―	50.77%